Chronic Obstructive Pulmonary Disease Endpoints Study
Status:
Completed
Trial end date:
2007-02-01
Target enrollment:
Participant gender:
Summary
This study will last for approximately 14 weeks and will involve 5 visits. The study is being
carried out to look at different ways of measuring the effect of drug treatment on COPD. COPD
is a respiratory disease which can affect your breathing and daily life. Symptoms of COPD can
include breathlessness, cough, and wheeze. COPD varies enormously from patient to patient.
The effects of drug treatment are usually measured by conducting lung function tests
(breathing tests) using a machine called a spirometer but this does not always provide a
complete picture of how well your COPD is responding. In this study we therefore want to look
at new and more sensitive ways of measuring COPD. The results of this research will help in
the assessment of new drugs for COPD in the future.
Phase:
Phase 4
Details
Lead Sponsor:
GlaxoSmithKline
Treatments:
Fluticasone Fluticasone Propionate, Salmeterol Xinafoate Drug Combination Fluticasone-Salmeterol Drug Combination Salmeterol Xinafoate Xhance